Chemistry:L-163,491
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C36H40N4O5S |
| Molar mass | 640.8 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
L-163,491 is an experimental drug which acts as a partial agonist of angiotensin II receptor type 1, and with lower affinity as an agonist of angiotensin II receptor type 2, mimicking the action of angiotensin II.[1] Its practical applications to date have been limited to scientific research into the function of the angiotensin receptor system,[2] but it has been suggested as a potential therapeutic agent for the treatment of inflammation of the lungs associated with certain viral diseases such as COVID-19.[3][4]
References
- ↑ "L-163,491 is a partial angiotensin AT(1) receptor agonist in the hindquarters vascular bed of the cat". European Journal of Pharmacology 404 (1–2): 213–9. September 2000. doi:10.1016/s0014-2999(00)00612-9. PMID 10980281.
- ↑ "Development of selective non-peptide angiotensin II type 2 receptor agonists". Journal of the Renin-Angiotensin-Aldosterone System 11 (1): 57–66. March 2010. doi:10.1177/1470320309347790. PMID 19880657.
- ↑ "Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases". ACS Central Science 6 (3): 315–331. 2020. doi:10.1021/acscentsci.0c00272. PMID 32226821.
- ↑ "Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury". Virologica Sinica 35 (3): 256–258. February 2020. doi:10.1007/s12250-020-00205-6. PMID 32034638.
 |  |
